Produktname:3-(2-chloropyrimidin-4-yl)-1H-indole
IUPAC Name:3-(2-chloropyrimidin-4-yl)-1H-indole
- CAS：945016-63-7
- Molekulare Formel：C12H8ClN3
- Reinheit：95%+
- Katalognummer：CM148712
- Molekulargewicht：229.67
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:945016-63-7
- Molekulare Formel:C12H8ClN3
- Schmelzpunkt:-
- SMILES-Code:ClC1=NC(=CC=N1)C1=CNC2=C1C=CC=C2
- Dichte:
- Katalognummer:CM148712
- Molekulargewicht:229.67
- Siedepunkt:
- Mdl-Nr.:MFCD16658942
- Lagerung:Keep in inert atmosphere, store at 2-8°C.
Category Infos
- Indoles
- Indole is a compound of pyrrole and benzene in parallel, also known as benzopyrrole. There are two combinations of pyrrole and benzene, called indole and isoindole, respectively. Many derivatives of indole have physiological and pharmacological activities, and can synthesize vasodilators, antihistamines, antipyretic analgesics, etc. in medicine, so indole is also a very important heterocyclic compound.
- indole company
- As a indole company,we sincerely welcome the new and old friends from home and abroad to synergize with our company and share the benefits and opportunities.
- Pyrimidines
- Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.
Column Infos
- Osimertinib
- TAGRISSO (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial.
TAGRISSO (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against central nervous system metastases. It is the first and only EGFR TKI recommended by NCCN Guidelines as an adjuvant treatment option for completely resected stage IB-IIIA, stage IIIB (T3, N2) EGFRm (exon 19 deletion, exon 21 L858R mutation) NSCLC.
Suche 
+86 21 5895 0110 
